Ceftazidime plus mezlocillin as initial antibiotic therapy in febrile neutropenic patients with haematological malignancy.
Sixty episodes of fever in neutropenic patients with haematological malignancy were treated with ceftazidime and mezlocillin. Improvement or temporary improvement was seen in 76% of patients with microbiologically or clinically documented infection. Fifty-seven per cent of episodes due to bacteraemia improved with the antibiotics. Escherichia coli and Staphylococcus aureus were the commonest pathogens isolated; bacteraemia due to Staph. epidermis was not encountered. The toxicity of ceftazidime plus mezlocillin was acceptable. Diarrhoea developed in 12% and a skin rash in 10%.
D001424:Bacterial Infections / Q000188:drug therapy; D002177:Candidiasis / Q000209:etiology; D002442:Ceftazidime / Q000008:administration & dosage*; D004338:Drug Combinations; D005334:Fever / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008802:Mezlocillin / Q000008:administration & dosage*; D009369:Neoplasms / Q000150:complications; D009503:Neutropenia / Q000150:complications; D018805:Sepsis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D004338:Drug Combinations; D002442:Ceftazidime; D008802:Mezlocillin